Communiqués Septerna, Inc.

Actions

SEPN

US81734D1046

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
38,51 ^USD	+2,01%		+4,65%	+38,13%

25/08	Septerna, Inc. annonce la nomination de Rajiv Patni au poste de Chief Medical Officer	CI
10/08	Septerna : réduction de la perte nette et hausse du chiffre d'affaires au deuxième trimestre	MT

Communiqués

10/09	Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
01/09	Septerna to Participate in Upcoming Investor Conferences	GL
25/08	Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer	GL
10/08	Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results	GL
08/06	Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting	BU
11/05	Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results	GL
05/05	Septerna to Present at Bank of America Securities Health Care Conference	GL
05/05	Septerna to Present at Bank of America Securities Health Care Conference	AQ
13/04	Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism	GL
09/03	Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results	GL
01/03	Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy	GL
24/02	Septerna to Present at TD Cowen 46th Annual Health Care Conference	GL
11/02	Septerna Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	AQ
10/02	Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
10/02	Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting	GL
10/02	Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting	AQ
08/01	Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer	GL
17/12	Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
25/11	Septerna to Participate in 8th Annual Evercore Healthcare Conference	GL
25/11	Septerna to Participate in 8th Annual Evercore Healthcare Conference	AQ
10/11	Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results	GL
03/11	Septerna to Participate in Upcoming Investor Conferences	GL
29/09/25	Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors	GL
27/08/25	Septerna to Participate in Upcoming Investor Conferences	GL
21/08/25	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases	GL